Minimal Residual Disease Status Predicts Progression-Free Survival in Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated with Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (KRd)

被引：0

作者：

Jasielec, Jagoda ^{[1
]}

Dytfeld, Dominik ^{[2
]}

Griffith, Kent A. ^{[3
]}

McDonnell, Kathryn ^{[1
]}

Lebovic, Daniel ^{[3
]}

Kandarpa, Malathi ^{[3
]}

Anderson, Tara ^{[3
]}

Mietzel, Melissa ^{[3
]}

Faham, Malek ^{[4
]}

Lee, Liana ^{[4
]}

Levy, Joan ^{[5
]}

Alonge, Mattina ^{[1
]}

Rosebeck, Shaun ^{[1
]}

Kaminski, Mark ^{[3
]}

Jakubowiak, Andrzej ^{[6
]}

机构：

[1] Univ Chicago, Med Ctr, Chicago, IL 60637 USA

[2] Poznan Univ Med Sci, Poznan, Poland

[3] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA

[4] Sequenta Inc, San Francisco, CA USA

[5] MMRC, Norwalk, CT USA

[6] Univ Chicago Med, Chicago, IL USA

来源：

BLOOD | 2014年 / 124卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[1] Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma
Dytfeld, Dominik
Jasielec, Jagoda
Griffith, Kent A.
Lebovic, Daniel
Vesole, David H.
Jagannath, Sundar
Al-Zoubi, Ammar
Anderson, Tara
Detweiler-Short, Kristen
Stockerl-Goldstein, Keith
Ahmed, Asra
Jobkar, Terri
Durecki, Diane E.
McDonnell, Kathryn
Mietzel, Melissa
Couriel, Daniel
Kaminski, Mark
Vij, Ravi
Jakubowiak, Andrzej J.
HAEMATOLOGICA, 2014, 99 (09) : E162 - E164
[2] Minimal Residual Disease (MRD) Detection By Deep Sequencing In Newly Diagnosed Multiple Myeloma Patients Treated With Carfilzomib, Lenalidomide and Dexamethasone
Mailankody, Sham
Korde, Neha
Faham, Malek
Kwok, Mary
Manasanch, Elisabet E.
Bhutani, Manisha
Tageja, Nishant
Kazandjian, Dickran
Weng, Li
Moorhead, Martin
Costello, Rene
Zhang, Yong
Zingone, Adriana
Burton, Debbie
Wu, Peter
Mulquin, Marcia
Zuchlinski, Diamond
Kurlander, Roger
Maric, Irina
Calvo, Katherine R.
Braylan, Raul C.
Yuan, Constance
Stetler-Stevenson, Maryalice
Arthur, Diane C.
Roschewski, Mark
Landgren, Ola
BLOOD, 2013, 122 (21)
[3] Prognostic and Predictive Gene Expression Profiling (GEP) Markers Confirmed in Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Treated Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts)
van Vliet, Martin
Jasielec, Jagoda
Dytfeld, Dominik
Vij, Ravi
Dumee, Belinda
Bosman, Lizanne
deBest, Leonie C. M.
Alonge, Mattina
Rosebeck, Shaun
Kandarpa, Malathi
McDonnell, Kathryn
Griffith, Kent A.
van Beers, Erik H.
Jakubowiak, Andrzej
BLOOD, 2014, 124 (21)
[4] Stem Cell Mobilization Characteristics for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab (KRd-Dara)
Bhutani, Manisha
Robinson, Myra
Atrash, Shebli
Watts, Nicole
Paul, Barry
Chhabra, Saurabh
Korde, Neha
Begic, Xhevahire
Foureau, David M.
Chung, David J.
Pineda-Roman, Mauricio
Koya, Brinda
Varga, Cindy
Ai, Jing
Daniels, Natonya
Norek, Sarah
Sutton, Sara A.
Anderson, Michelle B.
Jewell, Ashley N.
Eldridge, Paul W.
Acampora, Donna
Symanowski, James T.
Costa, Luciano J.
Usmani, Saad
Voorhees, Peter M.
BLOOD, 2022, 140 : 4393 - 4395
[5] MICRORNA (MIRNA) EXPRESSION PROFILING IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) TREATED WITH CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (CRD)
Jasielec, J. K.
Chen, J. L.
Rosebeck, S.
Dytfeld, D.
Griffith, K.
Alonge, M.
McDonnell, K.
Mietzel, M.
Couriel, D.
Kaminski, M.
Jakubowiak, A.
HAEMATOLOGICA, 2014, 99 : 366 - 366
[6] Minimal Residual Disease Assessment Using Euroflow-NGF in Patients with Multiple Myeloma Treated with a Combination of Carfilzomib, Lenalidomide, and Dexamethasone (KRD)
Yoroidaka, Takeshi
Takamatsu, Hiroyuki
Yamashita, Takeshi
Murata, Ryoichi
Yoshihara, Kyoko
Yoshihara, Satoshi
Ueda, Mikio
Nakao, Shinji
Matsue, Kosei
BLOOD, 2019, 134
[7] INITIAL RESULTS FROM A PHASE 2 STUDY OF CARFILZOMIB, LENALIDOMIDE, AND LOW-DOSE DEXAMETHASONE (KRD) PLUS AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)
Zimmerman, T. M.
Griffith, K.
Jasielec, J. K.
Rosenbaum, C. A.
McDonnell, K.
Marin, J.
Bakker, J.
Berdeja, J. G.
Vij, R.
Jakubowiak, A. J.
HAEMATOLOGICA, 2014, 99 : 103 - 103
[8] Longitudinal Assessment of Minimal Residual Disease (MRD) in the ATLAS Randomized Phase 3 Trial of Post-Transplant Treatment with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide (R) Alone in Patients with Newly Diagnosed Multiple Myeloma (NDMM)
Kubicki, Tadeusz
Dytfeld, Dominik
Wrobel, Tomasz
Jamroziak, Krzysztof
Robak, Pawel
Czyz, Jaroslaw
Tyczynska, Agata
Druzd-Sitek, Agnieszka
Giannopoulos, Krzysztof
Nowicki, Adam
Szczepaniak, Tomasz
Lojko-Dankowska, Anna
Matuszak, Magdalena
Gil, Lidia
Pula, Bartosz Michal
Rybka, Justyna
Majcherek, Maciej
Usnarska-Zubkiewicz, Lidia
Szukalski, Lukasz
Konska, Agnieszka
Zaucha, Jan M.
Walewski, Jan
Mikulski, Damian
Czabak, Olga
Robak, Tadeusz
Kruk-Kwapisz, Dorota
Lahoud, Oscar Boutros
Zonder, Jeffrey A.
Griffith, Kent
Stefka, Andrew T.
Jiang, Ken
Cooperrider, Jennifer H.
Derman, Ben A.
Jakubowiak, Andrzej J.
BLOOD, 2023, 142
[9] Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study
Meletios Dimopoulos
Michael Wang
Vladimir Maisnar
Jiri Minarik
William Bensinger
Maria-Victoria Mateos
Mihaela Obreja
Julie Blaedel
Philippe Moreau
Journal of Hematology & Oncology, 11
[10] Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study
Dimopoulos, Meletios
Wang, Michael
Maisnar, Vladimir
Minarik, Jiri
Bensinger, William
Mateos, Maria-Victoria
Obreja, Mihaela
Blaedel, Julie
Moreau, Philippe
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11

← 1 2 3 4 5 →